Glofitamab Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
J. Clin. Oncol 2021 Mar 19;[EPub Ahead of Print], M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, A Sureda, G Salles, J Martínez-Lopez, M Crump, DN Thomas, PN Morcos, C Ferlini, AE Bröske, A Belousov, M Bacac, N Dimier, DJ Carlile, L Lundberg, D Perez-Callejo, P Umaña, T Moore, M Weisser, MJ DickinsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.